Nona Biosciences enters collaboration agreement with Lycia Therapeutics

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. 

Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases. Through the collaboration, Lycia will leverage Nona’s proprietary Harbour Mice HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.

"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation.  We believe Lycia’s leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., chairman of Nona Biosciences said.

"Our LYTACs can uniquely address extracellular disease-driving targets that remain challenging for existing antibody and small molecule modalities. We look forward to deploying Nona Biosciences’ technology to advance the discovery of novel therapeutics for currently underserved patient populations,” said Steve Staben, Ph.D., chief scientific officer of Lycia Therapeutics.

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!